Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA “People Power” Could Take Sequestration Hit – Hamburg

This article was originally published in The Tan Sheet

Executive Summary

The FDA commissioner says a budget sequester would slow implementation of FDA Safety and Innovation Act provisions and reduce some overseas inspections. More emphasis could be placed on using systems that target the riskiest facilities to reduce the number of onsite inspections, Hamburg says.

You may also be interested in...



FDA Widens Search For Medical Products, Tobacco Deputy Commissioner

The winning candidate would be the third to hold the position in two years. FDA published two notices because the position “requires senior scientific experience in addition to senior executive leadership” and to reach a large applicant pool.

FDA Widens Search For Medical Products, Tobacco Deputy Commissioner

The winning candidate would be the third to hold the position in two years. FDA published two notices because the position “requires senior scientific experience in addition to senior executive leadership” and to reach a large applicant pool.

Congress Targets Sequester-Proof User Fees For FDA

Rep. Sam Farr says Congressional Budget Office scoring problems prevent releasing FDA’s fiscal 2013 user fees from being held in the budget sequester, but an amendment will be proposed to ensure the agency’s fiscal 2014 fees are included in its appropriations.

Related Content

Topics

UsernamePublicRestriction

Register

PS106223

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel